data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+Español
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+Italiano
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+Français
QQQ
––%
DIA
––%
SPY
––%
TLT
––%
GLD
––%
BTC/USD
––%
Contribute
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+Español
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+Italiano
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+Français
Personal Finance
Alts
Best Real Estate Crowdfunding Platforms
REITs Versus Crowdfunding
How to Invest in Artwork
Best Alternative Investments
Best Alternative Investment Platforms
Crypto
Cannabis
News
Earnings
Interviews
Deals
Regulations
Psychedelics
TV
YouTube
Video
Podcasts
Trading School
My Stocks
Tools
Premium
QQQ
––%
DIA
––%
SPY
––%
TLT
––%
GLD
––%
BTC/USD
––%
Galmed Pharmaceuticals
(NASDAQ:GLMD)
$0.60
-0.05[-7.69%]
At close: Jul 1
$0.6175
0.0175[2.92%]
After Hours: 9:30AM EDT
Day High/Low0.59 - 0.7
52 Week High/Low0.42 - 3.42
Open / Close0.64 / 0.62
Float / Outstanding21.6M / 25.1M
Vol / Avg.40.8K / 106.6K
Mkt Cap15.1M
P/E-
50d Avg. Price0.71
Div / Yield-
Payout Ratio-
EPS-0.3
Total Float21.6M

Galmed Pharmaceuticals (NASDAQ:GLMD), Quotes and News Summary

Galmed Pharmaceuticals (NASDAQ: GLMD)

Day High/Low0.59 - 0.7
52 Week High/Low0.42 - 3.42
Open / Close0.64 / 0.62
Float / Outstanding21.6M / 25.1M
Vol / Avg.40.8K / 106.6K
Mkt Cap15.1M
P/E-
50d Avg. Price0.71
Div / Yield-
Payout Ratio-
EPS-0.3
Total Float21.6M
Benzinga - 6 days ago
Benzinga - May 18, 2022, 6:10AM
Benzinga - May 17, 2022, 8:10AM
Benzinga - May 3, 2022, 2:11PM
Benzinga - May 3, 2022, 10:30AM
Benzinga - May 3, 2022, 6:13AM
Benzinga - May 3, 2022, 5:29AM
Benzinga - May 2, 2022, 7:25AM
Benzinga - Apr 28, 2022, 7:12AM
Benzinga - Jan 11, 2022, 7:31AM
Benzinga - Jan 10, 2022, 9:14AM
Benzinga - Jan 10, 2022, 7:46AM
Benzinga - Nov 8, 2021, 12:53PM
Benzinga - Nov 8, 2021, 7:33AM
Benzinga - Nov 8, 2021, 7:22AM
Benzinga - Nov 8, 2021, 5:50AM
load more
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product, aramchol, is a disease-modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis.
Read More

Earnings

see more
Q2 2022Est.ActualSurprise
EPS
(EXPECTED)2022-08-04
REV
Q1 2022Est.ActualSurprise
EPS-0.320-0.240 0.0800
REV0

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target

Galmed Pharmaceuticals Questions & Answers

Q
How do I buy Galmed Pharmaceuticals (GLMD) stock?
A

You can purchase shares of Galmed Pharmaceuticals (NASDAQ: GLMD) through any online brokerage.

View our list of the best stock brokerages.

Q
Who are Galmed Pharmaceuticals's (GLMD) competitors?
A

There are no as such competitors for Galmed Pharmaceuticals.

Q
What is the target price for Galmed Pharmaceuticals (GLMD) stock?
A

The latest price target for Galmed Pharmaceuticals (NASDAQ: GLMD) was reported by Raymond James on Wednesday, May 18, 2022. The analyst firm set a price target for 0.00 expecting GLMD to fall to within 12 months (a possible -100.00% downside). 3 analyst firms have reported ratings in the last year.

Q
Current Stock Price for Galmed Pharmaceuticals (GLMD)?
A

The stock price for Galmed Pharmaceuticals (NASDAQ: GLMD) is $0.6 last updated July 1, 2022, 8:00 PM UTC.

Q
Does Galmed Pharmaceuticals (GLMD) pay a dividend?
A

There are no upcoming dividends for Galmed Pharmaceuticals.

Q
When is Galmed Pharmaceuticals (NASDAQ:GLMD) reporting earnings?
A

Galmed Pharmaceuticals’s Q2 earnings are confirmed for Thursday, August 4, 2022.

Q
Is Galmed Pharmaceuticals (GLMD) going to split?
A

There is no upcoming split for Galmed Pharmaceuticals.

Q
What sector and industry does Galmed Pharmaceuticals (GLMD) operate in?
A

Galmed Pharmaceuticals is in the Healthcare sector and Biotechnology industry. They are listed on the NASDAQ.